Patterns of drug use and factors affecting adherence to medication in patients with rheumatoid arthritis: A prospective, observational, hospital- based study
DOI:
https://doi.org/10.15305/ijrci/v7i1/316Keywords:
RA, DMARDs, adherence, duration of RAAbstract
Introduction: RA affecting ~ 1% of the world population, is associated with high level of non-adherence in clinical practice. The adherence to RA treatment therapy is affected by multiple factors. The present study evaluated the factors affecting adherence to medications among RA patients.
Methodology: The prospective study was conducted from April 2014 to March 2015. Male and female subjects, aged ≥18 years, and diagnosed with RA were included in the study. Demographic data, disease- and treatment-related data, adverse event profile and investigation data were obtained from all the participants. Adherence to medication of the subjects was measured using adherence questionnaire. All the subjects were followed up at one month and at the end of 6 months. McNemar’s test was used to analyse the difference in adherence from baseline to follow up. All the statistical analyses were performed using SPSS statistical software, version 17.0.
Results: The study included 124 subjects, with a male to female ratio of 0.25:1, mean age of 45 years and RA duration of 5 years. Mono and combination drug therapies were used in 59.1% and 41.9% of the subjects respectively. Methotrexate was the most frequently used drug as a part of the regimen (82.3%). Among the subjects, 88 (71%) were found to be adherent. The comparison of various factors revealed significant difference only for the duration of RA (P 0.04).
Conclusion: The adherence to antirheumatic medications among RA patients remains moderate and factors such as rural residence and older age (>45 years) can be associated with good adherence to RA medication. The study also corroborates the previous literature evidence suggesting methotrexate as the commonly used drug for managing RA.
References
Global RA Network » About Arthritis and RA [Internet]. [cited 2018 Dec 9]. Available from: http://globalranetwork.org/project/disease-info/
Sharma S, Roshi, Tandon VR, Mahajan A. A Study Evaluating Adherence and Compliance of Anti-rheumatic Drugs in Women Suffering from Rheumatoid Arthritis. J Clin Diagn Res. 2015;9(11):OC01–4.
Bérard A, Solomon DH, Avorn J. Patterns of drug use in rheumatoid arthritis. J Rheumatol. 2000;27(7):1648–55.
Dutta SB, Beg MA, Bawa S, Kaur A, Vishal S. Prescribing pattern in Rheumatoid Arthritis patients in a tertiary care teaching hospital. International Journal of Basic & Clinical Pharmacology. 2017;6(6):1486–90.
Schmajuk G, Solomon DH, Yazdany J. Patterns of disease-modifying anti-rheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review. Arthritis Care Res (Hoboken). 2013;65(12):1927–35.
de Thurah A, Nørgaard M, Harder I, Stengaard-Pedersen K. Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A prospective cohort study. Rheumatol Int. 2010;30(11):1441–8.
van den Bemt BJF, Zwikker HE, van den Ende CHM. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8(4):337–51.
Goh ET, Soo AJX, Galloway J, Norton S, Nikiphorou E. THU0073 Factors associated with treatment adherence in rheumatoid arthritis: a systematic literature review. Annals of the Rheumatic Diseases. 2017;76(Suppl 2):226–226.
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002;46(2):328–46.
Pisetsky DS, St Clair EW. Progress in the treatment of rheumatoid arthritis. JAMA. 2001;286(22):2787–90.
Feldman CH, Lii J, Gopalakrishnan C, Franklin JM, Kim SC. THU0664 Treatment adherence to conventional and biologic disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2018;77(Suppl 2):526–526.
Salt E, Frazier S. Adherence to Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients: A Narrative Review of the Literature. Orthop Nurs. 2010;29(4):260–75.
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey [Internet]. ACR Meeting Abstracts. [cited 2018 Dec 9]. Available from: https://acrabstracts.org/abstract/non-adherence-to-disease-modifying-anti-rheumatic-drugs-in-patients-with-rheumatoid-arthritis-an-italian-survey-2/
Ragab OM, Zayed HS, Abdelaleem EA, Girgis AE. Effect of early treatment with disease-modifying anti-rheumatic drugs and treatment adherence on disease outcome in rheumatoid arthritis patients. The Egyptian Rheumatologist. 2017;39(2):69–74.
Joplin S, van der Zwan R, Joshua F, Wong PKK. Medication Adherence in Patients with Rheumatoid Arthritis: The Effect of Patient Education, Health Literacy, and Musculoskeletal Ultrasound. Biomed Res Int [Internet]. 2015 [cited 2018 Dec 9];2015. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427825/
Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int. 2007;27(8):743–6.
Wong M, Mulherin D. The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs. Musculoskeletal Care. 2007;5(3):148–59.
Pascual-Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J, Rull-Gabayet M. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther. 2009;11(1):R26.
Salt E, Frazier SK. Predictors of Medication Adherence in Patients with Rheumatoid Arthritis. Drug Dev Res. 2011;72(8):756–63.
Xie X, Yang H, Nie A, Chen H, Li J. Predictors of medication nonadherence in patients with systemic lupus erythematosus in Sichuan: a cross-sectional study . Patient Prefer Adherence. 2018 Aug 21;12:1505-1511.
Published
Issue
Section
License
Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the ‘Internet Journal of Rheumatology and Clinical Immunology’. All the published content, except where otherwise noted, is licensed under Creative Commons license (CC-BY).
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication of the manuscript in IJRCI, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
